Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Inventory Average (2016 - 2025)

Historic Inventory Average for Protalix BioTherapeutics (PLX) over the last 15 years, with Q3 2025 value amounting to $21.2 million.

  • Protalix BioTherapeutics' Inventory Average rose 1178.33% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 1178.33%. This contributed to the annual value of $20.1 million for FY2024, which is 1238.25% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Inventory Average stood at $21.2 million for Q3 2025, which was up 1178.33% from $20.3 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Inventory Average's 5-year high stood at $21.5 million during Q2 2024, with a 5-year trough of $13.5 million in Q1 2021.
  • In the last 5 years, Protalix BioTherapeutics' Inventory Average had a median value of $19.0 million in 2024 and averaged $18.1 million.
  • Its Inventory Average has fluctuated over the past 5 years, first skyrocketed by 5301.82% in 2021, then tumbled by 800.62% in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Inventory Average (Quarter) stood at $16.3 million in 2021, then fell by 4.03% to $15.7 million in 2022, then rose by 29.53% to $20.3 million in 2023, then decreased by 5.38% to $19.2 million in 2024, then rose by 10.26% to $21.2 million in 2025.
  • Its last three reported values are $21.2 million in Q3 2025, $20.3 million for Q2 2025, and $20.4 million during Q1 2025.